Research Article| Volume 30, SUPPLEMENT 3, S90-S91, 2008

Download started.


The role of current biomarkers in the management of lysosomal storage disorders

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Souillet G
        • Guffon N
        • Maire I
        • et al.
        Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources.
        Bone Marrow Transplant. 2003; 31: 1105-1117
        • Wraith JE
        • Beck M
        • Lane R
        • et al.
        Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: Results of a multinational study of recombinant human alpha-l-iduronidase (laronidase).
        Pediatrics. 2007; 120: e37-e46
        • Auray-Blais C
        • Cyr D
        • Ntwari A
        • et al.
        Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease.
        Mol Genet Metab. 2008; 93: 331-340
      1. PaschkeE, FaulerG, UrbanW, et al. Isoforms of globotriaosylceramide in urine can be used to identify female Fabry patients. Lecture presented at: 16th ESGLD Workshop-European Study Group of Lysosomal Diseases, September 27-30, 2007, Perugia, Italy.

        • Ohashi T
        • Sakuma M
        • Kitagawa T
        • et al.
        Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy.
        Mol Genet Metab. 2007; 92: 271-273
        • An Y
        • Young SP
        • Kishnani PS
        • et al.
        Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease.
        Mol Genet Metab. 2005; 85: 247-254
        • van den Hout HM
        • Hop W
        • van Diggelen OP
        • et al.
        The natural course of infantile Pompe's disease: 20 Original cases compared with 133 cases from the literature.
        Pediatrics. 2003; 112: 332-340
        • Aerts JM
        • Hollak CE
        Plasma and metabolic abnormalities in Gaucher's disease.
        Baillieres Clin Haematol. 1997; 10: 691-709
        • Deegan PB
        • Moran MT
        • McFarlane I
        • et al.
        Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease.
        Blood Cells Mol Dis. 2005; 35: 259-267